A global comparative study on real-world clinical and genomic differences in advanced biliary tract cancer.
Oluseyi Abidoye(Mayo Clinic), Tanios Bekaii‐Saab(WinnMed), Taro Shibuki(National Cancer Center Hospital East), Mitesh J. Borad(Jacksonville College), Masafumi Ikeda(National Cancer Center Hospital East), Nguyen H. Tran(The University of Sydney), Christina Wu(Mayo Clinic Hospital), Heidi Kosiorek(Mayo Clinic in Florida), Lewis R. Roberts(Mayo Clinic), Binbin Zheng-Lin(WinnMed), Hideaki Bando(Aichi Cancer Center), Cody Eslinger(WinnMed), Hani M. Babiker, Mohamad Bassam Sonbol(WinnMed), Takayuki Yoshino(University of Tsukuba), Takao Fujisawa(Osaka Prefectural Medical Center), Daniel H. Ahn(Mayo Clinic Hospital), Chigusa Morizane, Celine Hoyek(Mayo Clinic Hospital), Yoshiaki Nakamura(National Cancer Center Hospital East)
Cited by 0
Related Papers
Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases
|Hepatology|2018|4.7k
AASLD guidelines for the treatment of hepatocellular carcinoma
|Hepatology|2017|4.2k
Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer
|Cell|2018|2.8k
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
|Nature Reviews Gastroenterology & Hepatology|2020|2.5k
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2017|2.5k